Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2018 (2018), Article ID 5962624, 22 pages
https://doi.org/10.1155/2018/5962624
Research Article

Evaluating IL-21 as a Potential Therapeutic Target in Crohn’s Disease

1Global Research, Novo Nordisk A/S, Maaloev, Denmark
2Novo Nordisk LIFE In Vivo Pharmacology Centre, Frederiksberg, Denmark

Correspondence should be addressed to Thomas Lindebo Holm; moc.ksidronovon@hlht

Received 9 August 2017; Revised 5 February 2018; Accepted 13 February 2018; Published 10 April 2018

Academic Editor: Paul Enck

Copyright © 2018 Thomas Lindebo Holm et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. C. Baumgart and W. J. Sandborn, “Crohn’s disease,” The Lancet, vol. 380, no. 9853, pp. 1590–1605, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Ordás et al., “Ulcerative colitis,” The Lancet, vol. 380, pp. 1606–1619, 2014. View at Google Scholar
  3. R. B. Sartor, “Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis,” Nature Clinical Practice. Gastroenterology & Hepatology, vol. 3, no. 7, pp. 390–407, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Côté-Daigneault, M. Bouin, R. Lahaie, J. F. Colombel, and P. Poitras, “Biologics in inflammatory bowel disease: what are the data?” United European Gastroenterology Journal, vol. 3, no. 5, pp. 419–428, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. L. Wallace, L. B. Zheng, Y. Kanazawa, and D. Q. Shih, “Immunopathology of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 20, no. 1, pp. 6–21, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Gálvez, “Role of Th17 cells in the pathogenesis of human IBD,” ISRN Inflammation, vol. 2014, Article ID 928461, 14 pages, 2014. View at Publisher · View at Google Scholar
  7. G. Monteleone, F. Pallone, and T. T. MacDonald, “Emerging immunological targets in inflammatory bowel disease,” Current Opinion in Pharmacology, vol. 11, no. 6, pp. 640–645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Korn, E. Bettelli, W. Gao et al., “IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells,” Nature, vol. 448, no. 7152, pp. 484–487, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Suto, D. Kashiwakuma, S. I. Kagami et al., “Development and characterization of IL-21–producing CD4+ T cells,” The Journal of Experimental Medicine, vol. 205, no. 6, pp. 1369–1379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Lüthje, A. Kallies, Y. Shimohakamada et al., “The development and fate of follicular helper T cells defined by an IL-21 reporter mouse,” Nature Immunology, vol. 13, no. 5, pp. 491–498, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Spolski and W. J. Leonard, “Interleukin-21: a double-edged sword with therapeutic potential,” Nature Reviews. Drug Discovery, vol. 13, no. 5, pp. 379–395, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Coquet, K. Kyparissoudis, D. G. Pellicci et al., “IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production,” The Journal of Immunology, vol. 178, no. 5, pp. 2827–2834, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. G. Tangye, “Advances in IL-21 biology-enhancing our understanding of human disease,” Current Opinion in Immunology, vol. 34, pp. 107–115, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Asao, C. Okuyama, S. Kumaki et al., “Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex,” The Journal of Immunology, vol. 167, no. 1, pp. 1–5, 2001. View at Publisher · View at Google Scholar
  15. J. Parrish-Novak, S. R. Dillon, A. Nelson et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,” Nature, vol. 408, no. 6808, pp. 57–63, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Habib, S. Senadheera, K. Weinberg, and K. Kaushansky, “The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3,” Biochemistry, vol. 41, no. 27, pp. 8725–8731, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. W. J. Leonard and R. Spolski, “Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation,” Nature Reviews. Immunology, vol. 5, no. 9, pp. 688–698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Recher, L. J. Berglund, D. T. Avery et al., “IL-21 is the primary common γ chain-binding cytokine required for human B-cell differentiation in vivo,” Blood, vol. 118, no. 26, pp. 6824–6835, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Fantini, G. Monteleone, and T. T. MacDonald, “IL-21 comes of age as a regulator of effector T cells in the gut,” Mucosal Immunology, vol. 1, no. 2, pp. 110–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Schmitz, C. Schneider, A. Fröhlich et al., “IL-21 restricts virus-driven Treg cell expansion in chronic LCMV infection,” PLoS Pathogens, vol. 9, no. 5, article e1003362, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. B. Stockinger, M. Veldhoen, and B. Martin, “Th17 T cells: linking innate and adaptive immunity,” Seminars in Immunology, vol. 19, no. 6, pp. 353–361, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Monteleone, I. Monteleone, D. Fina et al., “Interleukin-21 enhances T-helper cell type I signaling and interferon-γ production in Crohn’s disease,” Gastroenterology, vol. 128, no. 3, pp. 687–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Hundorfean, M. F. Neurath, and J. Mudter, “Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 180–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Troncone, I. Marafini, F. Pallone, and G. Monteleone, “Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad,” International Reviews of Immunology, vol. 32, no. 5-6, pp. 526–533, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. M. A. Kleinschek, K. Boniface, S. Sadekova et al., “Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation,” The Journal of Experimental Medicine, vol. 206, no. 3, pp. 525–534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. Z. Hovhannisyan, J. Treatman, D. R. Littman, and L. Mayer, “Characterization of interleukin-17–producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases,” Gastroenterology, vol. 140, no. 3, pp. 957–965, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. van Leeuwen, D. J. Lindenbergh-Kortleve, H. C. Raatgeep et al., “Increased production of interleukin-21, but not interleukin-17A, in the small intestine characterizes pediatric celiac disease,” Mucosal Immunology, vol. 6, no. 6, pp. 1202–1213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. F. Pallone, D. Fina, R. Caruso, and G. Monteleone, “Role of IL-21 in inflammatory bowel disease,” Expert Review of Clinical Immunology, vol. 6, no. 4, pp. 537–541, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. Z. Wang, L. Ding, Z. Wang et al., “Circulating CD4+CXCR5+ T cells exacerbate B cell antibody production in Crohn’s disease through IL-21 secretion,” Immunological Investigations, vol. 44, no. 7, pp. 665–677, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Herber, T. P. Brown, S. Liang, D. A. Young, M. Collins, and K. Dunussi-Joannopoulos, “IL-21 has a pathogenic role in a lupus-prone mouse model and Its blockade with IL-21R.Fc reduces disease progression,” The Journal of Immunology, vol. 178, no. 6, pp. 3822–3830, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. D. Fina, M. Sarra, M. C. Fantini et al., “Regulation of gut inflammation and Th17 cell response by Interleukin-21,” Gastroenterology, vol. 134, no. 4, pp. 1038–1048.e2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. A. Bubier, S. M. Bennett, T. J. Sproule et al., “Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1110, no. 1, pp. 590–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. D. A. Young, M. Hegen, H. L. M. Ma et al., “Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 56, no. 4, pp. 1152–1163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. . C. Fantini, A. Rizzo, D. Fina et al., “IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells,” European Journal of Immunology, vol. 37, no. 11, pp. 3155–3163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Caruso, D. Fina, I. Peluso et al., “A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3α, by gut epithelial cells,” Gastroenterology, vol. 132, no. 1, pp. 166–175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Monteleone, R. Caruso, D. Fina et al., “Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21,” Gut, vol. 55, no. 12, pp. 1774–1780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Erman, I. Bilic, T. Hirschmugl et al., “Combined immunodeficiency with CD4 lymphopenia and sclerosing cholangitis caused by a novel loss-of-function mutation affecting IL21R,” Haematologica, vol. 100, no. 6, pp. e216–e219, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. E. Salzer, A. Kansu, H. Sic et al., “Early-onset inflammatory bowel disease and common variable immunodeficiency–like disease caused by IL-21 deficiency,” Journal of Allergy and Clinical Immunology, vol. 133, no. 6, pp. 1651–1659.e12, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Stepensky, B. Keller, O. Abuzaitoun et al., “Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency,” Haematologica, vol. 100, no. 2, pp. e72–e76, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Croce, V. Rigo, and S. Ferrini, “IL-21: a pleiotropic cytokine with potential applications in oncology,” Journal of Immunology Research, vol. 2015, Article ID 696578, 15 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Liu, X. Xia, W. Wu et al., “Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn’s disease,” Clinical & Experimental Immunology, vol. 173, no. 1, pp. 102–111, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Yu, X. Yang, L. Xia et al., “Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn’s disease with luminal lesions through balancing abnormal immune response in gut mucosa,” Mediators of Inflammation, vol. 2015, 9 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Kristensen, J. Eriksen, and K. Danø, “Localization of urokinase-type plasminogen activator messenger RNA in the normal mouse by in situ hybridization,” Journal of Histochemistry & Cytochemistry, vol. 39, no. 3, pp. 341–349, 2017. View at Publisher · View at Google Scholar · View at Scopus
  44. M. G. Willesen, P. Kristensen, and J. Rømer, “Co-localization of growth hormone Secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat,” Neuroendocrinology, vol. 70, no. 5, pp. 306–316, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Nevalainen, H. J. M. Blom, A. Guaitani, P. Hardy, B. R. Howard, and P. Vergara, “FELASA recommendations for the accreditation of laboratory animal science education and training: report of the Federation of European Laboratory Animal Science Associations Working Group on accreditation of laboratory animal science education and training,” Laboratory Animals, vol. 36, no. 4, pp. 373–377, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Lindebo Holm et al., “Pharmacological evaluation of the SCID T cell transfer model of colitis: as a model of Crohn’s disease,” International Journal of Inflammation, vol. 2012, Article ID 412178, 11 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Kjellev, D. Lundsgaard, S. S. Poulsen, and H. Markholst, “Reconstitution of Scid mice with CD4+CD25− T cells leads to rapid colitis: an improved model for pharmacologic testing,” International Immunopharmacology, vol. 6, no. 8, pp. 1341–1354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Holgersen, P. H. Kvist, A. K. Hansen, and T. L. Holm, “Predictive validity and immune cell involvement in the pathogenesis of piroxicam-accelerated colitis in interleukin-10 knockout mice,” International Immunopharmacology, vol. 21, no. 1, pp. 137–147, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Holgersen, P. H. Kvist, H. Markholst, A. K. Hansen, and T. L. Holm, “Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse — a model mimicking inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 8, no. 2, pp. 147–160, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Coskun, A. K. Olsen, T. L. Holm et al., “TNF-α-induced down-regulation of CDX2 suppresses MEP1A expression in colitis,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1822, no. 6, pp. 843–851, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. J. B. Seidelin, M. Coskun, P. H. Kvist, T. L. Holm, K. Holgersen, and O. H. Nielsen, “IL-33 promotes GATA-3 polarization of gut-derived T cells in experimental and ulcerative colitis,” Journal of Gastroenterology, vol. 50, no. 2, pp. 180–190, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. C. Becker, M. C. Fantini, and M. F. Neurath, “High resolution colonoscopy in live mice,” Nature Protocols, vol. 1, no. 6, pp. 2900–2904, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. K. Holgersen, B. Kutlu, B. Fox et al., “High-resolution gene expression profiling using RNA sequencing in patients with inflammatory bowel disease and in mouse models of colitis,” Journal of Crohn's and Colitis, vol. 9, no. 6, pp. 492–506, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. P. Brandtzaeg, H. Kiyono, R. Pabst, and M. W. Russell, “Terminology: nomenclature of mucosa-associated lymphoid tissue,” Mucosal Immunology, vol. 1, no. 1, pp. 31–37, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Sarra, I. Monteleone, C. Stolfi et al., “Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 16, no. 8, pp. 1332–1339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Liu, L. Yang, Y. Cui et al., “Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 15, no. 8, pp. 1133–1144, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. W. Jiang, J. Su, X. Zhang et al., “Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease,” Inflammation Research, vol. 63, no. 11, pp. 943–950, 2014. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Stolfi, A. Rizzo, E. Franzè et al., “Involvement of interleukin-21 in the regulation of colitis-associated colon cancer,” The Journal of Experimental Medicine, vol. 208, no. 11, pp. 2279–2290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. J. Yu, S. He, P. Liu et al., “Interleukin-21 promotes the development of ulcerative colitis and regulates the proliferation and secretion of follicular T helper cells in the colitides microenvironment,” Molecular Medicine Reports, vol. 11, no. 2, pp. 1049–1056, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Poholek and L. Harrington, “The role of interleukin-21 in the pathogenesis of inflammatory bowel disease,” The Journal of Immunology, vol. 188, Supplement 1, p. 123.45, 2012. View at Google Scholar
  61. C. Poholek and L. Harrington, “Interleukin-21 drives intestinal inflammation by bridging the adaptive and innate immune compartments,” The Journal of Immunology, vol. 190, Supplement 1, p. 171.3, 2013. View at Google Scholar
  62. A. Yeste, I. D. Mascanfroni, M. Nadeau et al., “IL-21 induces IL-22 production in CD4+ T cells,” Nature Communications, vol. 5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. I. Peluso, M. C. Fantini, D. Fina et al., “IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes,” The Journal of Immunology, vol. 178, no. 2, pp. 732–739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Wang, X. Jiang, J. Zhu et al., “IL-21/IL-21R signaling suppresses intestinal inflammation induced by DSS through regulation of Th responses in lamina propria in mice,” Scientific Reports, vol. 6, no. 1, p. 31881, 2016. View at Publisher · View at Google Scholar · View at Scopus